SCHEMBL20914262

SCHEMBL20914262

COc1cccc2nc(-c3c(C)[nH]c4c(-c5ccccc5)c(C(F)(F)F)nn4c3=O)[nH]c(=O)c12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TNKS O95271 4/20 0.39
▸ TNKS2 Q9H2K2 4/20 0.39
▸ PARP2 Q9UGN5 2/20 0.39
▸ GUSB P08236 3/20 0.38
▸ KDM4E B2RXH2 2/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ ELANE P08246 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ CYP1A1 P04798 2/20 0.36
▸ CYP1B1 Q16678 2/20 0.36
▸ PARP1 P09874 2/20 0.36
▸ HTT P42858 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CDK4 P11802 1/20 0.36
▸ CCND1 P24385 1/20 0.36
▸ PBRM1 Q86U86 1/20 0.36
▸ BRD4 O60885 1/20 0.36
▸ RECQL P46063 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20913902 0.86 TNKS (0.58) TNKSTNKS2PARP2PARP1
SCHEMBL20913938 0.85 TNKS (0.50) TNKSTNKS2PARP2GUSBKDM4E
SCHEMBL20914242 0.84 TNKS (0.42) TNKSTNKS2PARP2KDM4EALDH1A1
SCHEMBL20914113 0.82 KDM4E (0.45) KDM4EALDH1A1HPGDSMN1; SMN2POLB
SCHEMBL20914334 0.82 POLB (0.37) TNKSTNKS2PARP2KDM4EALDH1A1
SCHEMBL20913937 0.81 C1R (0.37) TNKSTNKS2PARP2KDM4EALDH1A1
SCHEMBL20914271 0.80 KDM4E (0.39) TNKSTNKS2KDM4EALDH1A1HPGD
SCHEMBL20914306 0.80 KDM4E (0.43) KDM4EALDH1A1HPGDSMN1; SMN2POLB
SCHEMBL20913971 0.79 POLB (0.45) KDM4EALDH1A1HPGDSMN1; SMN2POLB
SCHEMBL20914122 0.76 KDM4E (0.43) KDM4EALDH1A1HPGDSMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof NLRP3, NLRP1, P2RX7 TNKS 531/4885TNKS2 932/4885PARP2 1671/4885
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF NLRP3, NLRP1, P2RX7 TNKS 531/4885TNKS2 932/4885PARP2 1671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback